Photo from wikipedia
Key Points Question Is the US Food and Drug Administration (FDA)–recommended end point feasible in clinical trials of acupuncture for irritable bowel syndrome (IBS)? Findings In this pilot randomized clinical… Click to show full abstract
Key Points Question Is the US Food and Drug Administration (FDA)–recommended end point feasible in clinical trials of acupuncture for irritable bowel syndrome (IBS)? Findings In this pilot randomized clinical trial of 90 patients, the use of an FDA-recommended end point as the primary outcome was feasible for clinical trials of acupuncture for IBS. No significant between-groups differences in IBS symptom improvement were found. Meaning The findings of this pilot trial may provide a more accurate basis for assessing the efficacy of acupuncture for IBS in subsequent clinical trials.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!